Language
Country/Area
No result found
Dengue vaccine secrets: What are the differences between Dengvaxia and Qdenga?
Dengue fever, a mosquito-borne infectious disease caused by dengue virus, is mainly prevalent in tropical and subtropical regions, posing a major threat to public health. According to the World Health Organization, dengue affects the lives of millions of people worldwide, with millions of dengue infections recorded every year. However, with the development of vaccines, the situation has improved. This article will focus on the two vaccines for dengue fever - Dengvaxia and Qdenga, and the differences between them.
Basic concepts of dengue fever
Symptoms of dengue fever include high fever, headache, muscle and joint pain, rash, etc. Most patients will not show obvious symptoms, but a small number of people will develop severe dengue fever, leading to life-threatening situations. The disease is mainly transmitted by the Aedes aegypti mosquito, and the vaccine is being developed to eradicate the disease.
Dengvaxia Introduction
Dengvaxia is the first vaccine approved for the prevention and treatment of dengue fever and has been used in several countries since 2016. The vaccine is a live attenuated vaccine suitable for infected patients aged 6 to 45 years and is effective against all four dengue virus serotypes.
The use of Dengvaxia is limited to individuals who have already been infected because of the risk of antibody-dependent enhancement (ADE).
Qdenga Development
Qdenga, approved for use in 2022, is a new type of vaccine for use in individuals aged 4 years and older. Unlike Dengvaxia, Qdenga can cover individuals who have never been infected with dengue, making it more widely applicable.
Qdenga contains all four serotypes of dengue virus and provides protection in two doses, administered three months apart.
The main difference between the two
Although Dengvaxia and Qdenga are both used to prevent dengue fever, there are fundamental differences in their applicable populations and vaccination methods.
First, Dengvaxia is only recommended for people who have had a previous dengue infection, whereas Qdenga is suitable for individuals of all ages, regardless of previous infection history.
Effectiveness of vaccines
The protection rate of Dengvaxia is
There will be some improvement after one dose, but full protection is only optimal after completing three doses. The original intention of developing Qdenga was to provide more comprehensive protection. Current test data show that Qdenga has demonstrated good protective effects in preventing mild to severe dengue fever.
Safety of vaccination
The safety of vaccination is one of the important factors to consider. Dengvaxia was found to pose a certain risk to some uninfected people, namely, it may cause severe cases of dengue fever. Qdenga is designed to reduce this risk, making it a safer choice.
According to the latest clinical trial data, Qdenga shows more ideal effects in terms of safety, especially for people who have never been infected with dengue fever.
Vaccine usage and prospects
Although Dengvaxia and Qdenga have been approved and are being promoted in many countries around the world, medical institutions and public health departments still need to consider the local epidemic situation, vaccination rates, and the general public during implementation. Health awareness.With the continued spread of dengue fever, especially the alarming number of infections in recent years, the promotion and popularization of vaccines is crucial. Governments around the world are also stepping up the deployment and distribution of vaccines to prepare for possible dengue outbreaks.
In the future, with the advancement of technology and in-depth research on vaccines, we may see more effective solutions and vaccines to further control the spread of dengue fever. Nowadays, vaccines have become an important means to deal with the dengue fever epidemic. What do you think of this medical breakthrough? Do you think vaccines will be the key to curing dengue fever?
